Health economics

Telemedicine in Dermatology

Volumn , Issue , 2012, Pages 167-186

  Bensink, M E ^a,b,c   Scuffham, P A ^b   Smith, A C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879987166     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-20801-0_19     Document Type: Chapter

References (56)

1. Arrow K (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 53(5):941–73
2. Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford
3. Kernick D (2002) Getting health economics into practice. Radcliffe Medical Press, Oxford
4. Palmer S, Torgerson D (1999) Definitions of efficiency. BMJ 318(7191):1136
5. Asking focused questions: Centre for evidence based medicine (2009) Available at: http://www.cebm.net/index.aspx?o= 1036 Accessed 2011, August 31
6. Pitt M, Garside R, Stein K (2006) A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 154(6):1137–46
7. National Institute for Clinical Excellence (NICE) (2004) Guide to the methods of technology appraisal. London: NICE
8. Byford S, Raftery J (1998) Perspectives in economic evaluation. BMJ 316(7143):1529–30
9. Palmer S, Raftery J (1999) Opportunity cost. BMJ 318:1551–2
10. Patrick D, Erickson P (1993) Health status and health policy. Oxford Univeristy Press, New York
11. Nord E (1999) Cost-value analysis in health care: making sense out of QALYs. Cambridge University Press, Cambridge
12. Briggs A, O’Brien B (2001) The death of cost-minimization analysis? Health Econ 10(2):179–84
13. Vogenberg RE (2001) Introduction to applied pharmacoeconomics. McGraw-Hill, New York
14. Kind P, Lafata J, Matuszewski K, Raisch D (2009) The use of QALYs in clinical and patient decision-making: issues and prospects. Value Health 12(suppl 1):S27–30
15. Duru G, Auray J, Beresniak A, Lamure M, Paine A, Nicoloyannis N (2002) Limitations of the methods used for calculating quality adjusted life year values. Pharmacoeconomics 20:463–73
16. Boadway R, Bruce N (1984) Welfare economics. Basil Blackwell Publisher Ltd., Oxford
17. Little I (2002) A critique of welfare economics. Oxford University Press, Oxford
18. Sibbald B (1998) Understanding controlled trials: why are randomised controlled trials important? BMJ 316(7126):201
19. Glick H, Doshi J, Sonnad S, Polsky D (2007) Economic evaluation in clinical trials. Oxford University Press, Oxford
20. Raiffa C (1968) Decision analysis: introductory lectures on choices under uncertainty. Addison-Wesley, Reading
21. Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
22. Australian Government Department of Health and Ageing: MBS Online.Commonwealth of Australia. Available from: http://www.health.gov.au/internet/mbsonline/publishing. nsf/Content/Medicare-Benefits-Schedule-MBS-1. accessed 31 August, 2011
23. British Medical Association & Royal Pharmaceutical Society of Great Britain (2005) British National Formulary, No. 49. Pharmaceutical Press, Oxfordshire
24. Australian Taxation Office. Claiming a deduction for car expenses using the cents per kilometre method. Australian Government. Available from: http://www.ato.gov.au/individuals/content.asp?doc=/content/33874.htm&pc=001/002/013/008/004&mnu=1220&mfp=001/002&st=&cy=1. accessed 31 August, 2011
25. Cairns J (1994) Valuing future benefits. Health Econ 3:221–9
26. Torgerson D (1999) Discounting. BMJ 319(7214):914–5
27. Smith D, Gravelle H (2001) The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care 17(2):236–43
28. Australian Government Department of Health and Ageing (2008) Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Commonwealth of Australia
29. Australian Government Department of Finance and Deregulation (2007) The Australian government property ownership framework. Canberra
30. Chan H, Woo J, Chan W, Hjelm M (2001) Teledermatology in Hong Kong: a cost-effective method to provide service to the elderly patients living in institutions. Int J Dermatol 39(10):774–8
31. Borman P, Chatfield M, Damjanov I, Jackson P (2009) Design and analysis of method equivalence studies. Anal Chem 81(24):9849–57
32. Pater C (2004) Equivalence and noninferiority trials–are they viable alternatives for registration of new drugs? Curr Control Trials Cardiovasc Med 5(1):8
33. Mauskopf J, Sullivan S, Annemans L, Caro J, Mullins C, Nuijten M et al (2007) “Principles of good practice for budget impact analysis” report of the ISPOR task force on good research practices-budget impact analysis. Value Health 10(5):336–47
34. Chen S (2007) Dermatology quality of life instruments: sorting out the quagmire. J Invest Dermatol 127:2695–6
35. Chren M, Lasek R, Quinn L, Covinsky K (1997) Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol 108:103–7
36. Finlay A, Khan GCED (1994) Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210–6
37. Gusi N, Olivares P, Rajendram R (2010) The EQ-5D health related quality of life questionnaire. In: Preedy V, Watosn R (eds) Handbook of disease burdens and quality of life measures. Springer, New York, pp 87–99
38. Horsman J, Furlong W, Feeny D, Torrance G (2003) The health utilities index (HUI®): concepts, measurement properties and applications. Health Qaul Life Outcomes 1:54
39. Richardson J, Day N, Peacock S, Iezzi A (2004) Measurement of the quality of life for economic evaluation and the Assessment of Quality of Life (AQoL) Mark 2 Instrument. Aust Econ Rev 37(1):62–88
40. Brazier J, Roberts J (2004) The estimation of a preferencebased measure of health from the SF-12. Med Care 42(9):851–59
41. Brazier J, Harper R, Jones N, O’Cathain A, Thomas K, Usherwood T et al (1992) Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 305(6846):160–4
42. Ware J, Kosinski M, Keller S (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220–33
43. Schulman K, Seils D (2003) Clinical economics. In: Max M, Lynn J, eds. Interactive textbook on clinical symptom research. Bethesda: National Institutes of Health
44. Moreno-Ramirea D, Ferrandiz L, Ruiz-de-Casas A, Nieto- Garcia A, Moreno-Alvarez P, Galdeano R et al (2009) Economic evaluation of a store-and-forward teledermatology system for skin cancer patients. J Telemed Telecare 15:40–5
45. Thompson S, Barber J (2000) How should cost data in pragmatic randomised controlled trials be analysed? BMJ 320:1197–20
46. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A et al (2005) Best practices for economic evaluation alongside clinical trials: an ISPOR RCT-CEA task force report. Value Health 8:521–33
47. Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke W (2007) Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges 5(9): 762–8
48. Jiang G, Wu J, Williams G (2000) Fieller’s interval and the bootstrap-fieller interval for the incremental costeffectiveness ratio. Health Serv Outcome Res Methods 1(3–4): 291–303
49. Glick H, Doshi J, Sonnad S, Polsky D (2007) Economic evaluation in clinical trials. Oxford University Press, Oxford
50. TreeAge Software Inc. TreeAge Pro. Available from: http://www.treeage.com/products/overviewHealth.html. accessed March 27, 2009
51. Briggs A (1999) Handling uncertainty in economic evaluation. BMJ 319(7202):120
52. Drummond M (1996) Guidelines for authors and per reviewers of economic submissions to the BMJ. BMJ 313:275–83
53. Harris A, Hill S, Chin G, Li J, Walkom E (2008) The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004. Med Decis Making 28:713–22
54. Tan-Torres Edejer T, Haltussen R, Adam T, Hutubesay R, Acharya A, Evans D et al (eds) (2003) Making choice in health: WHO guide to cost-effectiveness analysis. WHO, Geneva
55. De Portu S, Del Giglio M, Altomare G, Arcangeli F, Berardesca E, Pinton P, Lotti T et al (2010) Cost-effectiveness analysis of TNF- a blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatol Ther 23(1):S7–S13
56. Black W (1990) The CE plane. Med Decis Making 10(3): 212–4